Comparative study on ABCB1-dependent efflux of anthracyclines and their metabolites: consequences for cancer resistance

References

• Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, Harrell PM, Trinh YT, Zhang Q, Urbatsch IL, et al. 2009. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science. 323(5922):1718–1722. doi: 10.1126/science.1168750.
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Lum BL, Fisher GA, Brophy NA, Ehsan MN, Halsey J, Sikic BI. 1994. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol. 12(4):835–842. doi: 10.1200/JCO.1994.12.4.835.
   PubMed Web of Science ®Google Scholar
• Callies S, de Alwis DP, Wright JG, Sandler A, Burgess M, Aarons L. 2003. A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979). Cancer Chemother Pharmacol. 51(2):107–118. doi: 10.1007/s00280-002-0542-3.
   PubMed Web of Science ®Google Scholar
• Capelôa T, Benyahia Z, Zampieri LX, Blackman MCNM, Sonveaux P. 2020. Metabolic and non-metabolic pathways that control cancer resistance to anthracyclines. Semin Cell Dev Biol. 98:181–191. doi: 10.1016/j.semcdb.2019.05.006.
   PubMed Web of Science ®Google Scholar
• Chen Q, Lin W, Yang J, Lin M, Lin X, Weng Y, Chen Y. 2021. Prognostic value of two polymorphisms, rs1045642 and rs1128503, in ABCB1 following taxane-based chemotherapy: a meta-analysis. Asian Pac J Cancer Prev. 22(1):3–10. doi: 10.31557/APJCP.2021.22.1.3.
   PubMedGoogle Scholar
• Ferreira RJ, Ferreira M-JU, dos Santos DJVA. 2013. Molecular docking characterizes substrate-binding sites and efflux modulation mechanisms within P-glycoprotein. J Chem Inf Model. 53(7):1747–1760. doi: 10.1021/ci400195v.
   PubMed Web of Science ®Google Scholar
• Gonzalez B, Akman S, Doroshow J, Rivera H, Kaplan WD, Forrest GL. 1995. Protection against daunorubicin cytotoxicity by expression of a cloned human carbonyl reductase cDNA in K562 leukemia cells. Cancer Res. 55(20):4646–4650.
   PubMed Web of Science ®Google Scholar
• Grigoreva TA, Sagaidak AV, Novikova DS, Tribulovich VG. 2022. Implication of ABC transporters in non-proliferative diseases. Eur J Pharmacol. 935:175327. doi: 10.1016/j.ejphar.2022.175327.
   PubMed Web of Science ®Google Scholar
• Halgren TA. 2009. Identifying and characterizing binding sites and assessing druggability. J Chem Inf Model. 49(2):377–389. doi: 10.1021/ci800324m.
   PubMed Web of Science ®Google Scholar
• Kim Y, Chen J. 2018. Molecular structure of human P-glycoprotein in the ATP-bound, outward-facing conformation. Science. 359(6378):915–919. doi: 10.1126/science.aar7389.
   PubMed Web of Science ®Google Scholar
• Krause W. 2019. Resistance to anti-tubulin agents: from vinca alkaloids to epothilones. Cancer Drug Resist. 2(1):82–106. doi: 10.20517/cdr.2019.06.
   PubMedGoogle Scholar
• Kuffel MJ, Ames MM. 1995. Comparative resistance of idarubicin, doxorubicin and their C-13 alcohol metabolites in human MDR1 transfected NIH-3T3 cells. Cancer Chemother Pharmacol. 36(3):223–226. doi: 10.1007/BF00685850.
   PubMed Web of Science ®Google Scholar
• May K, Minarikova V, Linnemann K, Zygmunt M, Kroemer HK, Fusch C, Siegmund W. 2008. Role of the multidrug transporter proteins ABCB1 and ABCC2 in the diaplacental transport of talinolol in the term human placenta. Drug Metab Dispos. 36(4):740–744. doi: 10.1124/dmd.107.019448.
   PubMed Web of Science ®Google Scholar
• Mora Lagares L, Novič M. 2022. Recent advances on P-glycoprotein (ABCB1) transporter modelling with in silico methods. Int J Mol Sci. 23(23):14804. doi: 10.3390/ijms232314804.
   PubMed Web of Science ®Google Scholar
• Mora Lagares L, Pérez-Castillo Y, Minovski N, Novič M. 2021. Structure-function relationships in the human p-glycoprotein (ABCB1): insights from molecular dynamics simulations. Int J Mol Sci. 23(1):362. doi: 10.3390/ijms23010362.
   PubMed Web of Science ®Google Scholar
• Nguyen PH, Sigdel KP, Schaefer KG, Mensah GAK, King GM, Roberts AG. 2020. The effects of anthracycline drugs on the conformational distribution of mouse P-glycoprotein explains their transport rate differences. Biochem Pharmacol. 174:113813. doi: 10.1016/j.bcp.2020.113813.
   PubMed Web of Science ®Google Scholar
• Pilotto Heming C, Muriithi W, Wanjiku Macharia L, Niemeyer Filho P, Moura-Neto V, Aran V. 2022. P-glycoprotein and cancer: what do we currently know? Heliyon. 8(10):e11171. doi: 10.1016/j.heliyon.2022.e11171.
   PubMed Web of Science ®Google Scholar
• Piska K, Koczurkiewicz P, Bucki A, Wójcik-Pszczoła K, Kołaczkowski M, Pękala E. 2017. Metabolic carbonyl reduction of anthracyclines—role in cardiotoxicity and cancer resistance. Reducing enzymes as putative targets for novel cardioprotective and chemosensitizing agents. Invest New Drugs. 35(3):375–385. doi: 10.1007/s10637-017-0443-2.
   PubMed Web of Science ®Google Scholar
• Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE, Gottesman MM. 2018. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev Cancer. 18(7):452–464. doi: 10.1038/s41568-018-0005-8.
   PubMed Web of Science ®Google Scholar
• Ross DD, Doyle LA, Yang W, Tong Y, Cornblatt B. 1995. Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance. Biochem Pharmacol. 50(10):1673–1683. doi: 10.1016/0006-2952(95)02069-1.
   PubMed Web of Science ®Google Scholar
• Sastry GM, Adzhigirey M, Day T, Annabhimoju R, Sherman W. 2013. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des. 27(3):221–234. doi: 10.1007/s10822-013-9644-8.
   PubMed Web of Science ®Google Scholar
• Sherman W, Day T, Jacobson MP, Friesner RA, Farid R. 2006. Novel procedure for modeling ligand/receptor induced fit effects. J Med Chem. 49(2):534–553. doi: 10.1021/jm050540c.
   PubMed Web of Science ®Google Scholar
• Zhou Z-Y, Wan L-L, Yang Q-J, Han Y-L, Li D, Lu J, Guo C. 2016. Nilotinib reverses ABCB1/P-glycoprotein-mediated multidrug resistance but increases cardiotoxicity of doxorubicin in a MDR xenograft model. Toxicol Lett. 259:124–132. doi: 10.1016/j.toxlet.2016.07.710.
   PubMed Web of Science ®Google Scholar